Clinical Trials
18 trialsNCT07162038 2026-06-05
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT07524530 2026-06-05
Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Not yet recruiting
NCT07359859 2026-05-27
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT03670966 2026-05-04
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
Phase 1/2 Recruiting
NCT01231412 2026-04-30
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 3 Completed
NCT04959175 2026-04-28
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT05327023 2026-04-28
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT06807606 2026-04-28
Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06926595 2026-04-03
GVHD-PTCy
Milton S. Hershey Medical Center
Phase 2 Recruiting
NCT02333162 2026-03-30
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
University of Chicago
Phase 1 Suspended
NCT01203722 2026-02-19
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT02861417 2026-02-17
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03032783 2026-01-29
A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity
Thomas Jefferson University
Phase 2 Completed
NCT03983850 2025-12-26
Optimizing PTCy Dose and Timing
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
NCT01349101 2025-12-15
A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors
Thomas Jefferson University
Phase 2 Completed
NCT06799195 2025-12-15
PTCYGVHD
University of Nebraska
Phase 2 Recruiting
NCT01810588 2025-09-02
Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT03712878 2025-08-22
2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies
Thomas Jefferson University
Phase 2 Completed